Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 10/20 | 0.36 |
| ▸ | CTSS | P25774 | 6/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294123 | 1.00 | CASP1 (0.41) | CASP1CA1CA2CA7ATM | |
| SCHEMBL25658173 | 0.90 | CA1 (0.42) | CA1CA2CA7ATMCYP2D6 | |
| SCHEMBL15071354 | 0.89 | CA1 (0.38) | CASP1CA1CA2CA7ATM | |
| SCHEMBL31295342 | 0.89 | CYP2D6 (0.47) | CASP1CA1CA2CA7ATM | |
| SCHEMBL15074960 | 0.89 | CYP2D6 (0.47) | CASP1CA1CA2CA7ATM | |
| SCHEMBL13633534 | 0.87 | CYP2D6 (0.40) | CASP1CA1CA2CA7ATM | |
| SCHEMBL29778323 | 0.87 | CYP2D6 (0.40) | CASP1CA1CA2CA7ATM | |
| SCHEMBL28969072 | 0.86 | ATM (0.36) | CA1CA2CA7ATMCTSK | |
| SCHEMBL28969069 | 0.86 | ATM (0.36) | CA1CA2CA7ATMCTSK | |
| SCHEMBL13674044 | 0.85 | CTSK (0.40) | CA1CA2CA7ATMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307534-A | LTA4H inhibitors and uses thereof | 上海海雁医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-7618982-B2 | Heteroarylpyrrolopyridinones active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-11-17 | — | — | US | disclosed |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | MAP3K1, MAP3K19, MAP3K3 | CASP1 2814/4885CA1 4431/4885CA2 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.